Follow
Joost Besseling
Joost Besseling
Junior doctor in Internal Medicine, Amsterdam Medical Center, the Netherlands
Verified email at amc.nl
Title
Cited by
Cited by
Year
Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcome
B Sjouke, DM Kusters, I Kindt, J Besseling, JC Defesche, EJG Sijbrands, ...
European heart journal 36 (9), 560-565, 2014
4482014
Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus
J Besseling, JJP Kastelein, JC Defesche, BA Hutten, GK Hovingh
JAMA 313 (10), 1029-1036, 2015
3692015
Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers
J Besseling, I Kindt, M Hof, JJP Kastelein, BA Hutten, GK Hovingh
Atherosclerosis 233 (1), 219-223, 2014
1932014
Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology
G De Backer, J Besseling, J Chapman, GK Hovingh, JJP Kastelein, ...
Atherosclerosis 241 (1), 169-175, 2015
1752015
Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality
J Besseling, GK Hovingh, R Huijgen, JJP Kastelein, BA Hutten
Journal of the American College of Cardiology 68 (3), 252-260, 2016
1562016
Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study
JJP Kastelein, J Besseling, S Shah, J Bergeron, G Langslet, GK Hovingh, ...
The Lancet 385 (9983), 2153-2161, 2015
1052015
Screening and treatment of familial hypercholesterolemia–Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014)
J Besseling, B Sjouke, JJP Kastelein
Atherosclerosis 241 (2), 597-606, 2015
462015
Selection of individuals for genetic testing for familial hypercholesterolaemia: development and external validation of a prediction model for the presence of a mutation …
J Besseling, JB Reitsma, D Gaudet, D Brisson, JJP Kastelein, GK Hovingh, ...
European heart journal 38 (8), 565-573, 2016
452016
Efficacy and safety of mipomersen sodium (Kynamro)
K Hovingh, J Besseling, J Kastelein
Expert opinion on drug safety 12 (4), 569-579, 2013
382013
LDL cholesterol goals in high-risk patients: how low do we go and how do we get there?
J Besseling, J van Capelleveen, JJP Kastelein, GK Hovingh
Drugs 73 (4), 293-301, 2013
232013
Intestinal cholesterol secretion: future clinical implications
L Jakulj, J Besseling, ES Stroes, AK Groen
Neth J Med 71 (9), 459-465, 2013
212013
EUROASPIRE Investigators. Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European Society of …
G De Backer, J Besseling, J Chapman, GK Hovingh, JJ Kastelein, ...
Atherosclerosis 241 (1), 169-175, 2015
182015
Homozygous autosomal dominant hypercholesterolemia in the Netherlands: prevalence, genotype-phenotype relationship and clinical outcome
B Sjouke, D Kusters, I Kindt, J Besseling, J Defesche, E Sijbrands, ...
Journal of the American College of Cardiology 63 (12 Supplement), A2050, 2014
182014
Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy
ML Hartgers, J Besseling, ES Stroes, J Wittekoek, JHW Rutten, J de Graaf, ...
Journal of clinical lipidology 12 (4), 972-980. e1, 2018
152018
Clinical Phenotype in Relation to the Distance-to-index-patient in Familial Hypercholesterolemia
J Besseling, R Huijgen, SS Martin, BA Hutten, JJP Kastelein, GK Hovingh
Atherosclerosis 246, 1-6, 2016
102016
Antisense oligonucleotides in the treatment of lipid disorders: pitfalls and promises
J Besseling, GK Hovingh, ES Stroes
Neth J Med 71 (3), 118-122, 2013
82013
Use of Palliative Chemotherapy and ICU Admissions in Gastric and Esophageal Cancer Patients in the Last Phase of Life: A Nationwide Observational Study
J Besseling, J Reitsma, JA Van Erkelens, MHJ Schepens, MPC Siroen, ...
Cancers 13 (145), 2021
72021
Is there a link between diabetes and cholesterol metabolism?
J Besseling, BA Hutten
Expert review of cardiovascular therapy 14 (3), 259-261, 2016
62016
predicting the presence of a mutation resulting in familial hypercholesterolemia-development of a prediction model in a cohort of 64,000 subjects
J Besseling, JB Reitsma, GK Hovingh, BA Hutten
Circulation 130 (suppl_2), A16172-A16172, 2014
42014
Attainment of LDL-C treatment target in familial hypercholesterolemia patients: A theoretical model exploring efficacy of current and novel lipid lowering therapies
ML Hartgers, J Besseling, GK Hovingh
Atherosclerosis 252, e43-e44, 2016
32016
The system can't perform the operation now. Try again later.
Articles 1–20